Skip to search formSkip to main contentSkip to account menu

MDL 101731

Known as: MDL 101,731, MDL-101,731, MDL101731 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tezacitabine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
Selective cytotoxic activity of a novel ribonucleoside diphosphate reductase inhibitor MDL-101,731 against thyroid cancer in vitro.
The dramatically increased number of new cases of disseminated children thyroid cancer in Belarus after the Chernobyl accident… 
1996
1996
In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor.
We examined the effects of MDL101731, a novel ribonucleoside reductase inhibitor, against human glioblastomas and neuroblastoma… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)